Potential for Advancements in HIV Weekly Treatment Options

HIV Weekly Treatment Options took a major step forward as Gilead and Merck reported that their investigational once-weekly combination of islatravir and lenacapavir successfully met the primary endpoint in two Phase 3 trials. The oral regimen maintained viral suppression in adults already controlled on daily therapy, offering the potential for a true long-acting tablet taken just once a week.

Switch Studies Deliver Clear Answers

The ISLEND-1 and ISLEND-2 trials enrolled only virologically suppressed participants and compared the new weekly tablet against leading daily regimens, including bictegravir/emtricitabine/tenofovir alafenamide. Both studies used the FDA snapshot algorithm at week 48 as the primary measure, providing regulators and clinicians with standardized, rigorous evidence of performance in real-world switch settings.

Non-Inferior Efficacy, Familiar Safety

Statistical non-inferiority was achieved in both the double-blind and open-label designs, with comparable rates of viral rebound and no new safety signals detected. These consistent results across different trial structures strengthen confidence that the HIV Weekly Treatment Options can preserve efficacy while reducing dosing burden.

Implications for Patients and Systems

By demonstrating that HIV Weekly Treatment Options can match daily therapy without introducing new risks, the data open the door to improved adherence, quality of life, and potentially lower long-term healthcare costs. Gilead and Merck’s clinical program now positions this combination as a possible first-in-class weekly oral HIV therapy, reshaping expectations for convenient, multi-mechanism antiretroviral innovation.

Next Steps Toward Approval

With positive 48-week data in hand, the partners plan to advance regulatory filings and continue follow-up through week 96. If approved, this regimen could fundamentally expand HIV Weekly Treatment Options for people seeking greater freedom from daily pills while maintaining uncompromising viral control.